Business & Industry

As European nations seek to stabilize their national health systems, the resulting regulatory changes are prompting a reassessment of market priority and supply chain reshoring. In a significant escalation of this trend, German lawmakers have finalized a sweeping health...

AstraZeneca has expanded its oncology pipeline through a $1.5 billion agreement with Dizal Pharma, securing the Zegfrovy global rights. This oral lung cancer therapy, also known as sunvozertinib, is an irreversible EGFR inhibitor. Currently, sunvozertinib is approved in China...

The modernization of regulatory frameworks is becoming essential to support the pharmaceutical industry’s transition toward advanced production models and to ensure the resilience of global supply chains. As innovative manufacturing technologies emerge, traditional oversight mechanisms must evolve to maintain...

The emergence of chimeric antigen receptor T cell therapy has been one of the most significant breakthroughs in the history of hematology oncology. By re engineering a patient’s own immune cells to recognize and attack cancer, researchers have achieved...

The oncology sector is witnessing a fundamental change in the way systemic radiation is delivered to patients. Historically, radiotherapy was administered from an external source, which, while effective at killing tumor cells, often caused significant damage to the surrounding...

The pharmaceutical industry has historically focused on a narrow subset of the human proteome. For decades, the majority of small molecule drugs were designed to bind to the active sites of enzymes or receptors, effectively inhibiting their function. While...

The biopharmaceutical sector is currently navigating an era of unprecedented growth and technological complexity. As the global drug pipeline shifts toward advanced modalities such as cell and gene therapies, bispecific antibodies, and complex mRNA formulations, the demands placed on...